Claims for Patent: 9,945,847

Summary for Patent: 9,945,847

Title:	Immunoassays using over-labeled fluorescent probes
Abstract:	The present disclosure provides immunoassays using one or more over-labeled fluorescent probes, which provides for rapid, accurate and quantitative detection of one or more target analytes in sample, reading fluorescent intensity. The disclosed immunoassays provide multiplexing capability with low cross-reactivity.
Inventor(s):	Chen; Henry J. X. (Saint Charles, MO)
Assignee:	ASSAYPRO, LLC (St. Charles, MO)
Application Number:	14/493,963
Patent Claims:	1. An immunoassay kit for conducting an immunoassay in a fluorescence plate reader to detect at least two analytes in a sample comprising: a solid support; a first capture antibody specific for a first analyte; a first over-labeled fluorescent probe capable of providing a detectable signal; and at least a second capture antibody specific for a second analyte and a second over-labeled fluorescent probe; wherein an over-labeled fluorescent probe comprises at least two conjugation moieties and fluorescent moieties, wherein each of the at least two conjugation moieties are labeled with at least two of the fluorescent moieties and are covalently conjugated to the over-labeled fluorescent probe. 2. The immunoassay kit according to claim 1, further comprising n additional capture antibodies, each n additional capture antibody specific for a different analyte, and n additional over-labeled fluorescent probes. 3. The immunoassay kit according to claim 2, wherein the first over-labeled fluorescent probe is specific for the first analyte, the second over-labeled fluorescent probe is specific for the second analyte, and any n additional over-labeled fluorescent probes are each specific for an n.sup.th additional analyte. 4. The immunoassay kit according to claim 2, wherein the first over-labeled fluorescent probe is specific for the first capture antibody, the second over-labeled fluorescent probe is specific for the second capture antibody, and any n additional over-labeled fluorescent probes are each specific for an n.sup.th capture antibody. 5. The immunoassay kit according to claim 2, wherein the first, second and any n additional capture antibodies are randomly immobilized on the solid support. 6. The immunoassay kit according to claim 1, wherein the fluorescent moieties are selected from the group consisting of Li-COR, CF fluorescent dyes, DyLight Dyes, Alexa Fluor, CY dyes, ATTO, Chromis dyes, R-phycocyanins, allophycocyanin, green fluorescent protein, fluorescent cDNA, and combinations thereof. 7. The immunoassay kit according to claim 6, wherein the fluorescent moieties are selected from the group consisting of DyLight 350, DyLight 405, DyLight 488, DyLight 594, DyLight 633, DyLight 650, ATTO 390, ATTO 565, ATTO, 590, ATTO 430LS, ATTO 490LS, and combinations thereof. 8. The immunoassay kit according to claim 1, wherein each over-labeled fluorescent probe specific for one analyte has a different fluorescent signal from the other over-labeled fluorescent probe specific for other analytes in the sample. 9. The immunoassay kit according to claim 1, wherein each over-labeled fluorescent probe specific for one capture antibody has a different fluorescent signal from the other over-labeled fluorescent probe specific for other capture antibodies. 10. The immunoassay kit according to claim 1, wherein the conjugation moieties are selected from the group consisting of BSA, Ovalbumin (OVA), Keyhole limpet hemocyanin (KLH), SEQ ID NO: 1 (KCKCKCKCKCKCKCK), and combinations thereof. 11. The immunoassay kit according to claim 1, wherein the conjugation moieties are the same for each over-labeled fluorescent probe. 12. The immunoassay kit according to claim 1, wherein the immunoassay has less than about 10% cross-reactivity with any one or more cross-reacting analytes present in the sample. 13. The immunoassay kit according to claim 1, wherein the immunoassay has less than about 5% cross-reactivity with any one or more cross-reacting analytes present in the sample. 14. The immunoassay kit according to claim 1, wherein at least one signal from each over-labeled fluorescent probes is detectable using a fluorescent intensity reader. 15. The immunoassay kit according to according to claim 1, wherein the solid support is selected from the group consisting of a magnetic particle, bead, test tube, microtiter plate, cuvette, membrane, a scaffolding molecule, film, filter paper, disc, and chip. 16. The immunoassay kit according to according to claim 1, wherein at least one analyte is selected from the group consisting of Human alpha1-acid Glycoprotein, Human alpha Fetoprotein, Human alpha1-Microglobulin, Human alpha2-HS-Glycoprotein, Human Adiponectin, Mouse Adiponectin, Rat Adiponectin, Mouse Albumin, Rabbit Albumin, Swine Albumin, Human Pancreatic Amylase, Rat ANP, Human alpha1-antitripsin, Human Apolipoprotein Al, Human ApolipoproteinAII, Human Apolipoprotein B, Human Apolipoprotein CI, Human Apolipoprotein CII, Human Apolipoprotein CIII, Human Apolipoprotein E, Human Apolipoprotein H, Human Antithrombin III, Mouse Antithrombin II, Rat BNP-32, Rat BNP-45, Human Complement C1q, Human Complement C1r, Human Complement C1, Human Complement C2, Human Complement C3, Human Complement C4, Human Complement C5, Human Complement C6, Human Complement C7, Human Complement C8, Human Complement C9, Human Ceruloplasmin, Rat Ceruloplasmin, Human C-Reactive Protein, Rat C-Reactive Protein, Canine C-Reactive Protein, Mouse C-Reactive Protein, Human Elastase (ELA-2), Human Complement Factor B, Human Complement Factor D, Mouse Complement Factor D, Human Complement Factor H, Human Complement Factor I, Human Ferritin, Canine Fibrinogen, Human Fibrinogen, Mouse Fibrinogen, Rat Fibrinogen, Human Fibronectin, Mouse Fibronectin, Human Factor IX, Human Factor V, Human Factor VII, Human Factor X, Human Factor XI, Human Factor XII, Human Factor XIII, Human GC-Globulin, Human GPIIb/IIIa, Bovine Haptoglobulin, Canine Haptoglobulin, Human Haptoglobulin, Swine Haptoglobulin, Rat Haptoglobulin, Human Hemopexin, Human IgA, Human IgD, Human IgG3, Human IgG, Human IgM, Human Kininogen (HMW), Human Lactoferrin, Human Lp(a), Human Lysozyme, Human alpha 2 Macroglobulin, Mouse alpha Macroglobulin, Rat alpha Macroglobulin, Human beta 2-Microglobulin, Rat beta 2-Microglobulin, Human PAI-1, Human PAI-1/tPA, Human Prekallikrein (PK), Bovine Plasminogen, Human Plasminogen, Mouse Plasminogen, Rat Plasminogen, Human Prealbumin, Human Protein C, Human Protein S, Human Protein Z, Human Prothrombin, Swine Prothrombin, Mouse Prothrombin, Human RBP4, Human RBP, Mouse RBP4, Rat RBP4, Canine RBP4, Human Serum Amyloid P, Human TAT Complex, Mouse TAT Complex, Human TF, Human TFPI, Human Thrombin, Human tPA, Human Transferrin, Rat Transferrin, Mouse Transferrin, Human uPA, Human vWF, Human Alpha 1 Antichymotrypsin, Human PSA, Human Total, PSA, Human IgE, Human ApoJ, Human C1qBP, Human Cancer Antigens, Human Cystatin C and combinations thereof.

Details for Patent 9,945,847

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2033-09-23
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2033-09-23
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2033-09-23
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2033-09-23
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2033-09-23
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2033-09-23